Novel biomarkers of abdominal aortic aneurysm disease: Identifying gaps and dispelling misperceptions

33Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Abdominal aortic aneurysm (AAA) is a prevalent and potentially life-threatening disease. Early detection by screening programs and subsequent surveillance has been shown to be effective at reducing the risk of mortality due to aneurysm rupture. The aim of this review is to summarize the developments in the literature concerning the latest biomarkers (from 2008 to date) and their potential screening and therapeutic values. Our search included human studies in English and found numerous novel biomarkers under research, which were categorized in 6 groups. Most of these studies are either experimental or hampered by their low numbers of patients. We concluded that currently no specific laboratory markers allow screeing for the disease and monitoring its progression or the results of treatment. Further studies and studies in larger patient groups are required in order to validate biomarkers as cost-effective tools in the AAA disease. © 2014 Demetrios Moris et al.

Cite

CITATION STYLE

APA

Moris, D., Mantonakis, E., Avgerinos, E., Makris, M., Bakoyiannis, C., Pikoulis, E., & Georgopoulos, S. (2014). Novel biomarkers of abdominal aortic aneurysm disease: Identifying gaps and dispelling misperceptions. BioMed Research International. Hindawi Publishing Corporation. https://doi.org/10.1155/2014/925840

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free